ChromaDex Corp (CDXC): Market Capitalization-to-Revenue Ratio

Niagen patent protection ensures stable wholesale volume, although advertising expenses limit retail margins. Strict FDA oversight and unique formulas create a powerful barrier to entry for competitors. ChromaDex Corporation (CDXC) maintains its brand authority through its status as a biohacking leader. The median P/S on GURU.Markets contains data where the value is held at 6.00, allowing for a real-time assessment of current capitalization relative to annual sales.

The P/S ratio measures the market value of one dollar of revenue, allowing an investor to determine the extent of overpayment for a business relative to its actual sales. Analyzing this price-to-sales chart confirms that the distribution expansion and financial autonomy of ChromaDex Corporation (CDXC) create a foundation for sustainable capitalization, turning the current valuation into an indicator of the company's long-term fundamental strength.